Comparative Pharmacology
Head-to-head clinical analysis: CHOLESTYRAMINE LIGHT versus QUESTRAN LIGHT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLESTYRAMINE LIGHT versus QUESTRAN LIGHT.
CHOLESTYRAMINE LIGHT vs QUESTRAN LIGHT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby preventing enterohepatic recirculation of bile acids and promoting hepatic conversion of cholesterol to bile acids, reducing serum LDL-cholesterol.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby reducing enterohepatic circulation of bile acids and promoting conversion of cholesterol to bile acids in the liver.
4 g orally once or twice daily, increased gradually to 4 g 1-6 times daily; maintenance 4-24 g/day in divided doses.
4 grams (one packet or one level scoop) orally once or twice daily, with a maximum of 24 grams per day. Dose may be increased by 4 grams daily at weekly intervals as needed.
None Documented
None Documented
Not applicable; cholestyramine is not absorbed systemically and has no plasma half-life; clinical effect duration reflects gastrointestinal transit time.
Not applicable; cholesteryamine resin is not absorbed systemically; half-life refers to GI transit time (~2-4 hours).
Primarily fecal as bile acid complex; <0.05% renal excretion of unchanged drug; negligible systemic absorption.
Primarily fecal (as resin-bound bile acids); less than 0.05% renally excreted unchanged.
Category C
Category C
Bile Acid Sequestrant
Bile Acid Sequestrant